|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01515 CR MEDICAL
Nominal 
2.550 +0.005 (+0.196%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 4,478,824 | -1.016% | 9,175,645 | 9,854,790 | 10,107,500 | 7,901,287 |
| Cost of Sales | (3,658,938) | -4.022% | (7,734,872) | (8,044,964) | (8,201,663) | (6,595,452) |
| Gross Profit | 819,886 | 15.067% | 1,440,773 | 1,809,826 | 1,905,837 | 1,305,835 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | (30) | (32,153) | (208,926) | (510) | |
| Change in FV & Impairment on Others | (20,290) | 78.170% | (22,284) | (7,921) | (272,228) | (136,130) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 41,487 | -12.567% | 78,338 | 98,603 | 90,780 | 88,068 | |
| Profit / (Loss) before Taxation | 394,138 | -22.433% | 747,665 | 838,670 | 492,921 | 422,941 | |
| Taxation | (74,750) | -44.164% | (191,567) | (166,923) | (165,031) | (94,660) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (54,486) | 56.898% | (60,154) | (105,872) | (70,210) | (62,426) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 264,902 | -21.978% | 495,944 | 565,875 | 257,680 | 265,855 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 14,998 | -34.452% | 40,965 | 62,125 | 57,031 | (22,202) |
| Depreciation & Amortisation | 289,445 | 0.220% | 584,927 | 618,896 | 610,863 | 486,406 |
| Directors' Emoluments | -- | -- | -- | 11,776 | 10,515 | 10,618 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 21.000 | -22.222% | 39.000 | 45.000 | 20.000 | 21.000 |
| DPS (cts) | 5.000 | -- | 13.400 | 13.200 | 6.000 | 3.344 |
| Dividend Payout Ratio (%) | 23.810% | -- | 34.359% | 29.333% | 30.000% | 15.923% |
| Cash flow per share ($) | -- | -- | 1.075 | 1.005 | 0.945 | 0.684 |
| NBV per share ($) | 5.176 | -- | 5.053 | 4.792 | 4.482 | 7.331 |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 264,902 |
| %Change | -21.978% |
| EPS / (LPS) | RMB 0.210 |
| NBV Per Share (¥) | RMB 5.176 |